AstraZeneca Receives FDA Approval for Truqap in HR-Positive, HER2-Negative Breast Cancer
UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced last week that it has received regulatory...
Alphamab Oncology’s JSKN003 ADC: Promising Preliminary Data in Advanced Solid Tumors
Alphamab Oncology (HKG: 9966) has released preliminary data from a Phase I clinical study on...
Final Results of China’s Round 9 Volume-Based Procurement Tender Announced
The National Allied Procurement Office has released the finalized results and tender bid allocations for...
BMS’s Augtyro Receives FDA Approval for ROS1-Positive NSCLC
The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS, NYSE: BMY)...
CDE Releases 76th Batch of Chemical Generic Reference Preparations
The Center for Drug Evaluation (CDE) has released the 76th batch of chemical generic reference...
Yipinhong Pharmacy’s AR882 Shows Promise in Gout Treatment in Phase II Study
China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced positive data from a Phase II...
Easton Pharmaceutical Receives FDA Approval for Generic Nalmefene
Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced receiving Abbreviated New Drug Application (ANDA)...
University of Hong Kong to Host Infectious Disease Labs by UN’s Vaccine Institute and Cambridge University
The University of Hong Kong (HKU) is poised to host new infectious disease laboratories established...
BeiGene Ltd Opens Global Industrialization Base for Small-Molecule Drugs in Suzhou
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the inauguration of its small-molecule...
Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia
Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A/S (NASDAQ: ASND) and Chinese healthcare...
Jiangxi Rimag Group Eyes Hong Kong IPO to Expand Medical Imaging Services
Jiangxi Rimag Group Co., Ltd (HKG: 2522), a China-based medical imaging specialist, is planning an...
Vertex Pharmaceuticals and CRISPR Therapeutics Receive Conditional Approval for CRISPR Gene-Editing Therapy
Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) have received conditional approval from the...
Q32 Bio Reclaims Development Rights to Anti-IL-7Rα Biologic from Amgen
Biotechnology firm Q32 Bio has announced its decision to reclaim full development and commercial rights...
Daewoong Pharma and Meheco International Expand Partnership for China’s Market Entry
Daewoong Pharma (KRX: 069620), a leading South Korean pharmaceutical company, has reportedly signed a memorandum...
SinoMab BioScience’s Suciraslimab IND Accepted for Review by China’s NMPA
SinoMab BioScience Ltd (HKG: 3681), a Hong Kong-based biotechnology company, has announced that the National...
Shanghai Henlius Biotech Reports 84.0% YOY Revenue Growth in Q3 2023 Financials
Shanghai Henlius Biotech Inc., (HKG: 2696) a prominent player in the biopharmaceutical industry, has published...
Sino Medical Sciences Technology’s HT Supreme Stent Gains Brazilian Market Approval
Sino Medical Sciences Technology Inc., (SHA: 688108) a leading China-based medical device company, has announced...
Gilead’s Kite Expands Partnership with Arcellx for Innovative Cell Therapies
Gilead (NASDAQ: GILD), a leading biopharmaceutical company, has announced an expansion of its 2022 partnership...
AbbVie Partners with Sinopharm to Enhance Novel Drug Accessibility and Patient Management
US pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a strategic partnership with Sinopharm Group...
Fujian Cosunter’s COVID-19 Therapy GST-HG171/Ritonavir NDA Accepted by NMPA
Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a China-based pharmaceutical company, has announced that its...